Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial

Autor:	Dominik Paul Modest, Daniel Oruzio, Klaus Zellmann, S. Klein, Thomas Decker, Johann Mittermueller, Volker Heinemann, M. Schulze, Sebastian Stintzing, Wolfgang Abenhardt, Ruediger P. Laubender, Ludwig Fischer von Weikersthal, Hermann F. Dietzfelbinger, Gerhard Puchtler, Holger G. Hass, Martina Stauch, Ursula Vehling-Kaiser, Ulrich Mansmann, Herbert W. Kappauf, Christopher Haberl
Rok vydání:	2012
Předmět:	Oncology Cancer Research medicine.medical_specialty Cetuximab business.industry Colorectal cancer Tumor shrinkage medicine.disease digestive system diseases First line treatment Internal medicine Overall survival medicine In patient business neoplasms medicine.drug
Zdroj:	Journal of Clinical Oncology. 30:3588-3588
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2012.30.15_suppl.3588
Popis:	3588 Background: This study investigated the impact of early tumor-shrinkage (ETS) on progression-free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated within the AIO KRK-0104-trial. ETS was previously shown to be a predictor of treatment response to cetuximab. The present analysis, for the first time, evaluates the correlation of ETS with outcome parameters in patients undergoing capecitabine-based therapy. It also aims to correlate the predictive value of ETS and cetuximab-induced skin toxicity. Methods: The AIO KRK0104 trial was performed as a randomised study comparing capecitabine/oxaliplatin (CAPOX) plus cetuximab to capecitabine/irinotecan (CAPIRI) plus cetuximab in the first-line treatment of mCRC. 121 patients were available for evaluation of ETS at 6 weeks. ETS was defined as a relative change of ≥20% in the sum of the longest diameters of target lesions compared to baseline. Results: Tumors of 63 patients (71% KRAS wild-type (wt), 100% skin reactions) developed ETS, 58 tumors did not develop ETS (53% KRAS wt, 86% skin reactions). ETS was associated with prolonged PFS (8.9 vs. 4.7 months, p-line therapy ETS correlates with prolonged PFS and OS. ETS also correlates with cetuximab-induced skin toxicity. Both parameters may therefore serve as post-randomisation surrogate markers of favourable outcome for cetuximab-based treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8c9696c66d79dc0b59051fb98948118d https://doi.org/10.1200/jco.2012.30.15_suppl.3588 Zobrazit plný text záznamu